ALENDOR 70 70 mg/1 tableta tableta 波斯尼亚和黑塞哥维那 - 克罗地亚文 - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alendor 70 70 mg/1 tableta tableta

pliva d.o.o.sarajevo - alendronska kiselina - tableta - 70 mg/1 tableta - 1 tableta sadrži: 70 mg alendronske kiseline (u obliku alendronatnatrijum, trihidrata)

ALENDOR 70 70 mg/1 tableta tableta 波斯尼亚和黑塞哥维那 - 克罗地亚文 - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alendor 70 70 mg/1 tableta tableta

pliva d.o.o.sarajevo - alendronska kiselina - tableta - 70 mg/1 tableta - 1 tableta sadrži: 70 mg alendronske kiseline (u obliku alendronatnatrijum, trihidrata)

Natrijev hidrogenkarbonat Medice 500 mg meke želučanootporne kapsule 克罗地亚 - 克罗地亚文 - HALMED (Agencija za lijekove i medicinske proizvode)

natrijev hidrogenkarbonat medice 500 mg meke želučanootporne kapsule

medice arzneimittel pütter gmbh & co. kg, kuhloweg 37, kuhlo, iserlohn, north rhine-westphalia, njemačka - natrijev hidrogenkarbonat - želučanootporna kapsula, meka - 500 mg - urbroj: jedna kapsula sadrži 500 mg natrijevog hidrogenkarbonata

Gemcitabin Sandoz 40 mg/ml koncentrat za otopinu za infuziju 克罗地亚 - 克罗地亚文 - HALMED (Agencija za lijekove i medicinske proizvode)

gemcitabin sandoz 40 mg/ml koncentrat za otopinu za infuziju

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - gemcitabinklorid - koncentrat za otopinu za infuziju - 40 mg/ml - urbroj: 1 ml koncentrata za otopinu za infuziju sadrži 40 mg gemcitabina u obliku gemcitabinklorida

Descovy 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

descovy

gilead sciences ireland uc - эмтрицитабин, Тенофовир alafenamide - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv-1).

Vemlidy 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

vemlidy

gilead sciences ireland uc - tenofovir alafenamid fumarat - hepatitis b - antivirusni lijekovi za sustavnu uporabu - vemlidy is indicated for the treatment of chronic hepatitis b (chb) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.

Biktarvy 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

biktarvy

gilead sciences ireland uc - bictegravir, эмтрицитабин, Тенофовир alafenamide, фумарат - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (vidi odjeljak 5.

Humira 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

humira

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - molimo pogledajte dokument s informacijama o proizvodu.

Celsentri 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

celsentri

viiv healthcare b.v. - maraviroka - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only ccr5-tropic hiv-1 detectable,.

Delstrigo 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

delstrigo

merck sharp & dohme b.v. - doravirine, lamivudin, Тенофовир дизопроксил фумарат - hiv infekcije - antivirusni lijekovi za liječenje hiv infekcija, kombinacija - delstrigo indiciran za liječenje odraslih osoba zaraženih hiv-1, bez prošlosti ili ovih dokaza otpornost do klase ННИОТ, lamivudin ili Тенофовир. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.